Eovist

(Gadoxetate Disodium)

PreclinicalSmall molecule

Bayer

Eovist is one of 31 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Preclinical

1 2

Sovaldi

Gilead

Preclinical

1 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Hepsera

Doptelet

1 6

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 7

Vermox

WWim Janssens

Preclinical

1 8

Valemetostat

Bristol-Myers Squibb

Preclinical

1 9

Alcohol

Astellas

Preclinical

—10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalActive, not recruiting

Hepatocellular Carcinoma

NCT02156739

Q4 2028

Post-ApprovalRecruiting

Study completion

NCT04373564

Clinical

Trials by Indication[1]

Liver Cancer1 trial

MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer

Completed·UUniversity of Southern California·Phase 1·NCT02578602·26 enrolled

MRI1 trial

Eovist vs. Dotarem Healthy Volunteer MRI

Completed·—·Phase 4·NCT02431598·44 enrolled

Contrast Agent1 trial

Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases

Terminated·UUniversity of Colorado, Denver·Phase 4·NCT04973007·10 enrolled

Magnetic Resonance Imaging1 trial

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

Terminated· Bayer logo

Bayer·Phase 3·NCT02084628·1 enrolled

Hepatocellular Carcinoma1 trial

Radiologic Detection and Characterization of Benign and Malignant Liver Lesions in Contrast-Enhanced MRI

Active, not recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT02156739·100 enrolled

1 more indication

Unspecified1 trial

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Recruiting·GGuerbet·Phase 4·NCT04373564·2,076 enrolled

Regulatory

FDA Approval Timeline[4]

Jul 3, 2008

EOVIST

NDA NDA022090

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Gadoxetate Disodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gadoxetate Disodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gadoxetate Disodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022090). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

Eovist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Trials by Indication[1]

Liver Cancer1 trial

MRI1 trial

Contrast Agent1 trial

Magnetic Resonance Imaging1 trial

Hepatocellular Carcinoma1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News